--- title: "Survodutide: Dosing & Vendor Prices — BodyHackGuide" description: "Survodutide: dosing protocols, mechanism & side effects, 61 PubMed studies. Compare verified vendor prices." lang: en json-ld: | [ { "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "Home", "item": "https://www.bodyhackguide.co/" }, { "@type": "ListItem", "position": 2, "name": "Compounds", "item": "https://www.bodyhackguide.co/compare" }, { "@type": "ListItem", "position": 3, "name": "Survodutide" } ] }, { "@context": "https://schema.org", "@type": "MedicalWebPage", "name": "Survodutide", "description": "Survodutide (BI 456906) is a once-weekly subcutaneous dual GLP-1 / glucagon receptor agonist developed by Boehringer Ingelheim and Zealand Pharma. As of 2026 it is in Phase 3 clinical trials (SYNCHRONIZE program) for obesity and metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH). Reported Phase 2 weight-loss results from late 2024 trials approached 19% body-weight reduction at the highest dose, placing it in the same outcome tier as Eli Lilly's retatrutide. Unlike pure GLP-1 agonists (semaglutide, tirzepatide's GLP-1 component), survodutide's glucagon agonism is hypothesized to drive higher resting energy expenditure and direct hepatic lipid mobilization - important mechanisms for MASH resolution where weight loss alone is insufficient.", "lastReviewed": "2026-05-04T11:33:51.993+00:00", "url": "https://www.bodyhackguide.co/compound/survodutide", "author": { "@type": "Person", "name": "BioChonch", "url": "https://www.bodyhackguide.co/about", "jobTitle": "Founder & Lead Researcher", "sameAs": [ "https://x.com/bodyhackguide", "https://reddit.com/r/BodyHackGuide", "https://reddit.com/r/BrainHackGuide", "https://reddit.com/r/Biohackingher" ], "worksFor": { "@type": "Organization", "name": "BodyHackGuide", "url": "https://www.bodyhackguide.co" } }, "reviewedBy": { "@type": "Person", "name": "BioChonch", "url": "https://www.bodyhackguide.co/about", "jobTitle": "Founder & Lead Researcher", "sameAs": [ "https://x.com/bodyhackguide", "https://reddit.com/r/BodyHackGuide", "https://reddit.com/r/BrainHackGuide", "https://reddit.com/r/Biohackingher" ], "worksFor": { "@type": "Organization", "name": "BodyHackGuide", "url": "https://www.bodyhackguide.co" } }, "publisher": { "@type": "Organization", "name": "BodyHackGuide", "url": "https://www.bodyhackguide.co" }, "mainContentOfPage": { "@type": "WebPageElement", "cssSelector": "main" }, "about": { "@type": "Drug", "name": "Survodutide", "alternateName": [ "BI 456906", "Boehringer GLP-1/glucagon" ], "description": "Survodutide (BI 456906) is a once-weekly subcutaneous dual GLP-1 / glucagon receptor agonist developed by Boehringer Ingelheim and Zealand Pharma. As of 2026 it is in Phase 3 clinical trials (SYNCHRONIZE program) for obesity and metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH). Reported Phase 2 weight-loss results from late 2024 trials approached 19% body-weight reduction at the highest dose, placing it in the same outcome tier as Eli Lilly's retatrutide. Unlike pure GLP-1 agonists (semaglutide, tirzepatide's GLP-1 component), survodutide's glucagon agonism is hypothesized to drive higher resting energy expenditure and direct hepatic lipid mobilization - important mechanisms for MASH resolution where weight loss alone is insufficient.", "activeIngredient": "Survodutide", "administrationRoute": "Subcutaneous", "mechanismOfAction": "Dual receptor agonism: simultaneously activates the GLP-1 receptor (suppressing appetite, slowing gastric emptying, improving glucose-dependent insulin secretion) AND the glucagon receptor (raising basal energy expenditure and stimulating hepatic lipolysis). The glucagon arm differentiates survodutide from semaglutide/tirzepatide. Hepatic glucagon receptor activation drives fatty acid oxidation in liver tissue, producing MASH improvement (histologic reduction without worsening of fibrosis in Phase 2 trials).", "legalStatus": "Not approved for human use — research chemical", "warning": "For research purposes only. Not for human consumption." } }, { "@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "What is Survodutide used for in research?", "acceptedAnswer": { "@type": "Answer", "text": "Survodutide (BI 456906) is a once-weekly subcutaneous dual GLP-1 / glucagon receptor agonist developed by Boehringer Ingelheim and Zealand Pharma. As of 2026 it is in Phase 3 clinical trials (SYNCHRONIZE program) for obesity and metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH). Reported Phase 2 weight-loss results from late 2024 trials approached 19% body-weight reduction at the highest dose, placing it in the same outcome tier as Eli Lilly's retatrutide. Unlike pure GLP-1 agonists (semaglutide, tirzepatide's GLP-1 component), survodutide's glucagon agonism is hypothesized to drive higher resting energy expenditure and direct hepatic lipid mobilization - important mechanisms for MASH resolution where weight loss alone is insufficient." } }, { "@type": "Question", "name": "What forms does Survodutide come in?", "acceptedAnswer": { "@type": "Answer", "text": "Survodutide is available in vials, capsules, and sprays forms." } }, { "@type": "Question", "name": "How much does Survodutide cost?", "acceptedAnswer": { "@type": "Answer", "text": "Pricing varies by vendor and form." } }, { "@type": "Question", "name": "How do I compare Survodutide vendors?", "acceptedAnswer": { "@type": "Answer", "text": "Compare prices, payment methods, shipping, and COA scores across 0 vendors." } } ] }, { "@context": "https://schema.org", "@type": "Organization", "@id": "https://www.bodyhackguide.co#organization", "name": "BodyHackGuide", "alternateName": "BHG", "url": "https://www.bodyhackguide.co", "logo": { "@type": "ImageObject", "url": "https://www.bodyhackguide.co/logo.png", "width": 512, "height": 512 }, "description": "Evidence-based research reference for peptides and nootropics. 124+ compound profiles, interactive dosing calculators, real-time vendor pricing, and trust-scored vendor reviews scored on a public, reproducible methodology applied to every vendor. BodyHackGuide and BHG Labs share common ownership, and we earn a commission on purchases through our links.", "foundingDate": "2024", "founder": { "@id": "https://www.bodyhackguide.co/about#person" }, "sameAs": [ "https://x.com/bodyhackguide", "https://reddit.com/r/BodyHackGuide", "https://reddit.com/r/BrainHackGuide", "https://reddit.com/r/Biohackingher", "https://discord.gg/Mhq5UdRYBA" ], "knowsAbout": [ "Peptide research", "Nootropic research", "Biohacking", "Compound dosing", "Vendor transparency" ], "publishingPrinciples": "https://www.bodyhackguide.co/editorial-standards", "ethicsPolicy": "https://www.bodyhackguide.co/editorial-standards", "diversityPolicy": "https://www.bodyhackguide.co/editorial-standards" } ] --- [Skip to content](#main-content) ## Research Use Only This site is an **educational resource** for research compounds. We do **not endorse** human consumption of any compound. BodyHackGuide and **BHG Labs share common ownership**; we rank every vendor on the same public methodology, and we earn a commission on purchases through our links. By entering, you confirm you are **21 years of age or older** and agree to our [Terms](/terms) & [Privacy Policy](/privacy). I'm 21+ — Enter SiteLeave site [![BodyHackGuide](/assets/bodyhackguide-logo-DOzZNUyh.webp)BodyHackGuide ](/) [Compare](/compare)[Wiki](/wiki)[Vendors](/vendors)[Deals](/deals)[Stacks](/stack-builder)[Nootropics](/nootropics)[Tools](/tools) Learn Community Search ⌘K [Sign In](/auth?returnTo=%2Fcompound%2Fsurvodutide) 100K+ researchers trust BodyHackGuide — Join [r/BodyHackGuide](https://reddit.com/r/bodyhackguide) 1. [Home](/) 2. [Compounds](/compare) 3. Survodutide [Where to buy Survodutide](/buy/survodutide) [Survodutide coupon codes](/coupons/survodutide) [Survodutide protocol](/protocol/survodutide) [Alternatives to Survodutide](/alternatives-to/survodutide) [Survodutide side effects](/side-effects/survodutide) 1. [Home](/) 3. [Compounds](/compare) 5. Survodutide # Survodutide GLP-1 / Glucagon Dual Agonist Phase 3 (SYNCHRONIZE trials) Download PDF Also known as: BI 456906, Boehringer GLP-1/glucagon Survodutide (BI 456906) is a once-weekly subcutaneous dual GLP-1 / glucagon receptor agonist developed by Boehringer Ingelheim and Zealand Pharma. As of 2026 it is in Phase 3 clinical trials (SYNCHRONIZE program) for obesity and metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH). Half-Life: ~100 hours (about 4 days), supporting once-weekly dosing Route: Subcutaneous MW: ~4.9 kDa (acylated peptide) [61 PubMed Studies](https://pubmed.ncbi.nlm.nih.gov/?term=survodutide) Last reviewed: May 4, 2026 [ 61 PubMed Studies ](https://pubmed.ncbi.nlm.nih.gov/?term=survodutide)[ GLP-1 / Glucagon Dual Agonist Category ](/wiki#cat-glp-1-/-glucagon-dual-agonist) Phase 3 (SYNCHRONIZE trials) Research Stage OverviewChemical InfoDosing & ProtocolsInteractionsResearchCompare PricesRelated ## Overview ### At A Glance Mechanism Dual receptor agonism: simultaneously activates the GLP-1 receptor (suppressing appetite, slowing gastric emptying, improving glucose-dependent insulin secretion) AND the glucagon receptor (raising basal energy expenditure and stimulating hepatic lipolysis). The glucagon arm diff… Half-Life ~100 hours (about 4 days), supporting once-weekly dosing Dosing Once weekly subcutaneous Dose Range 600-6000 mcg (0.6-6 mg) weekly research dosingmcg Routes Subcutaneous Common Vials 5mgmg 10mgmg Potential Benefits Up to 19% body weight reduction in Phase 2 trials MASH (steatohepatitis) histologic improvement without worsening of fibrosis in a Phase 2 trial (investigational; not resolution or approved use) Once-weekly dosing convenience Glucagon-driven energy expenditure increase Hepatic lipid mobilization Safety Notes Common Nausea (dose-dependent) Vomiting Diarrhea Decreased appetite Injection site reaction Serious Thyroid C-cell tumor signal in rodents (class label) Pancreatitis risk (GLP-1 class) Tachycardia possible from glucagon arm ### Overview Survodutide (BI 456906) is a once-weekly subcutaneous dual GLP-1 / glucagon receptor agonist developed by Boehringer Ingelheim and Zealand Pharma. As of 2026 it is in Phase 3 clinical trials (SYNCHRONIZE program) for obesity and metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH). Reported Phase 2 weight-loss results from late 2024 trials approached 19% body-weight reduction at the highest dose, placing it in the same outcome tier as Eli Lilly's retatrutide. Unlike pure GLP-1 agonists (semaglutide, tirzepatide's GLP-1 component), survodutide's glucagon agonism is hypothesized to drive higher resting energy expenditure and direct hepatic lipid mobilization - important mechanisms for MASH resolution where weight loss alone is insufficient. ### Potential Research Fields Obesity MASH/NASH Type 2 diabetes GLP-1 receptor Glucagon receptor ## Chemical Information IUPAC Name Not yet available CAS Number Not yet available Molecular Formula C-rich peptide (sequence not publicly disclosed) Molecular Mass ~4.9 kDa (acylated peptide) ## Dosing & Protocols ### Unlock Dosing Protocols Free account gets you: - View beginner, intermediate & advanced protocols - See weight-based dosing calculations - Access cycle length & frequency data [Create free account](/auth)[Sign in](/auth) 2,800+ researchers already in ## Research ### Unlock Research Data Free account gets you: - Browse PubMed study summaries - See clinical trial phases & results - Access mechanism of action details [Create free account](/auth)[Sign in](/auth) 2,800+ researchers already in ## Interactions ### Contraindications Personal or family history of medullary thyroid carcinoma (MTC) or MEN2 syndrome. Pregnancy and breastfeeding. Active pancreatitis. Severe gastroparesis or active inflammatory bowel disease. Research Disclaimer This interaction data is compiled from published research and community reports. It may not be exhaustive. Always consult a healthcare professional before combining compounds. [Sign in for alerts ](/auth) No listings found for Survodutide. Get Survodutide Price Drop Alerts Set a target price and we'll notify you when any vendor drops below it. [Sign in to set alerts](/auth) ### Sign in to leave a review Reviews on BodyHackGuide are tied to verified user accounts and moderated before publishing. Sign in (free, no spam) to share your experience with Survodutide. [Sign in](/auth) [ View Full Dosage Guide → Protocols, calculator & safety for Survodutide ](/guides/dosage/survodutide) ### Research Score 66 61 PubMed studies ### Quality Indicators Data Completeness 75% Description Mechanism of Action Chemical Data Dosing Protocols Safety Profile PubMed Studies Interactions Vendor Listings Research Credibility 61 PubMed studies Well-researched compound ### Quick Facts Half-Life ~100 hours (about 4 days), supporting once-weekly dosing Molecular Weight ~4.9 kDa (acylated peptide) Administration Subcutaneous Trial Phase Phase 3 (SYNCHRONIZE trials) ### Safety Profile Common Side Effects - • Nausea (dose-dependent) - • Vomiting - • Diarrhea - • Decreased appetite - • Injection site reaction [Full Dosage Guide](/guides/dosage/survodutide)[Calculate Your Dose](/tools/reconstitution) Research Disclaimer This information is for educational and research purposes only. Not intended as medical advice. Consult a healthcare professional before use. ## Frequently Asked Questions What is Survodutide used for in research? Survodutide (BI 456906) is a once-weekly subcutaneous dual GLP-1 / glucagon receptor agonist developed by Boehringer Ingelheim and Zealand Pharma. As of 2026 it is in Phase 3 clinical trials (SYNCHRONIZE program) for obesity and metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH). Reported Phase 2 weight-loss results from late 2024 trials approached 19% body-weight reduction at the highest dose, placing it in the same outcome tier as Eli Lilly's retatrutide. Unlike pure GLP-1 agonists (semaglutide, tirzepatide's GLP-1 component), survodutide's glucagon agonism is hypothesized to drive higher resting energy expenditure and direct hepatic lipid mobilization - important mechanisms for MASH resolution where weight loss alone is insufficient. What forms does Survodutide come in? Survodutide is available in vials, capsules, and sprays forms. How much does Survodutide cost? Pricing varies by vendor and form. How do I compare Survodutide vendors? Compare prices, payment methods, shipping, and COA scores across 0 vendors. ## Research Tools [ ### Peptide Calculator Reconstitution & syringe units ](/tools/reconstitution)[ ### Reconstitution Guide How to mix, step by step ](/guides/how-to-reconstitute-peptides)[ ### Nasal Spray Calc mL per actuation ](/tools/intranasal)[ ### Half-Life Visualizer Decay curves ](/tools/halflife) Free 2026 Peptide Cheat Sheet — 50 pages, PDF Reconstitution math, concentration charts, half-lives, and vendor trust tiers. The reference we wish we had on day one. [Download Free](/guides/peptide-cheat-sheet-download?utm_source=compound-survodutide) ### Need bloodwork before starting? Full hormone + metabolic panels from Anabolic Insights. Code CHONCH for first-order discount. [Order Bloodwork](https://anabolicinsights.ai/?ref=nwm2zjb) ![BodyHackGuide](/assets/bodyhackguide-logo-DOzZNUyh.webp) ### BodyHackGuide Your biohacking research hub — compound pricing, brain health protocols, dosing tools, and vendor reviews. [support@bodyhackguide.co](mailto:support@bodyhackguide.co) [](https://discord.gg/Mhq5UdRYBA)[](https://reddit.com/r/BodyHackGuide)[](https://x.com/bodyhackguide) Explore #### Explore - [Compare prices](/compare) - [Research suppliers](/vendors) - [Deals](/deals) - [Coupons](/coupons) - [Nootropics](/nootropics) - [Brain health](/brain-health) - [Blog](/blog) - [Guides](/guides) Tools #### Tools - [Reconstitution](/tools/reconstitution) - [Dosage calculator](/tools/dosage) - [Half-life visualizer](/tools/halflife) - [COA lookup](/tools/coa) - [Cost calculator](/tools/cost-calculator) - [Stack builder](/stack-builder) - [All tools →](/tools) Trust & vendors #### Trust & vendors - [Vendor directory](/vendors) - [Trust scorecard](/vendors/scorecard) - [Get BHG verified](/vendors/get-vetted) - [Scoring methodology](/vendors/methodology) - [Peptide cheatsheet](/guides/peptide-cheat-sheet-download) Company #### Company - [About](/about) - [Affiliate disclosure](/affiliate-disclosure) - [Editorial standards](/editorial-standards) - [Creators](/creators) - [Coaches](/coaches) - [Privacy](/privacy) - [Terms](/terms) - [Full site directory →](/site-directory) **Ownership & Affiliate Disclosure:** BodyHackGuide and BHG Labs share common ownership. We rank every vendor on the same public, reproducible [methodology](/vendors/methodology), and we earn a commission from purchases made through our links at no extra cost to you. Full details in our [affiliate disclosure](/affiliate-disclosure). **Research Disclaimer:** All compounds listed are for laboratory and research purposes only. Not for human consumption. This site does not sell, distribute, or promote any products. Always consult a qualified healthcare professional and comply with local regulations. © 2026 BodyHackGuide. All rights reserved. · [Terms](/terms) · [Privacy](/privacy) hi 👋